Astrazeneca Pharma India Ltd.

8,213

-156 (-1.9%)growUp

As on April 30, 2026
SectorHealthcare
IndustryPharmaceuticals & Biotechnology
Basic IndustryPharmaceuticals
Market Cap20,625 Cr
P/E Ratio177.4
Dividend Yield0.19 %
Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock_ipo_icon.webpUnlock Stock of the Month

T&C*

Company Information


Market Insights
Open8,431.5
High8,465.5
NSE SymbolASTRAZEN
Close8,213
Low8,102
BSE Symbol506820
Previous Years High/Low
1 Year High10,691
3 Year High10,691
5 Year High10,691
1 Year Low7,551.5
3 Year Low3,125
5 Year Low2,445.7

Technicals


IndicatorsValueSignal
5-DMA8,424.1Bearish
10-DMA8,450.7Bearish
20-DMA8,289.42Bearish
50-DMA8,481.18Bearish
100-DMA8,606.19Bearish
200-DMA8,816.19Bearish

Historical Performance


1 Year
-5.4%
3 Years
157.6%
5 Years
110.2%
10 Years
614%

Shareholding Pattern


Values Analysis


Loading chart...

Profit & Loss

Below figures are in Rs. Crores


Compounded Sales Growth
10 Years:27.1
5 Years:15.6
3 Years:16.3
TTM:5.8
Compounded Profit Growth
10 Years:14
5 Years:9.9
3 Years:13.4
TTM:-6.4
Stock Price CAGR
10 Years:21.7
5 Years:16
3 Years:37.1
TTM:-5.4
Return on Equity
10 Years:2.1
5 Years:37.3
3 Years:39.7
last year:46.3

Quarterly Results

Below figures are in Rs. Crores


ParticularsSep-2024Dec-2024Mar-2025Jul-2025Sep-2025
Sales1,70,7541,35,9361,28,5521,22,1891,05,161
Expenses63,04256,55752,45745,45934,856
Operating Profit1,07,71279,37976,09676,73070,304
OPM %63%58%59%63%67%
Other Income33,91231,75927,33324,87918,947
Interest77,78058,58459,24862,13753,713
Depreciation2,3451,6811,3851,2771,221
Profit Before Tax61,49850,87342,79638,19534,318
Tax %25%25%26%29%35%
Net Profit46,14938,15131,85727,29622,446
EPS in Rs8369585042

Balance Sheet

Below figures are in Rs. Crores


0%
Positive
(80 to 100)
Neutral
(60 to 79)
Negative
(0 to 59)
  • The stock has a high PE of 177.4, indicating expensive valuation or elevated growth expectations.
  • Over the last three years, the stock delivered a strong 3-year price CAGR of 37.2%, indicating sustained price appreciation.
  • The stock carries a low beta of 0.4, suggesting lower volatility than the broader market.
  • In the last financial year, the company reported an EBITDA of ₹2946 million, reflecting positive operating performance.
  • In the previous financial year, the company generated revenue of ₹17163 million, indicating a large and established business.

Investment Calculator


Investment Amount:

Investment Amount: ₹ 1000000
Current Value: ₹ 981125.3
No. of Shares: 119 (Approx)
Performance:-1.9%
P/L: ₹-18874.7
NIFTY Performance: -1.4%
1 day Top Gainers
SymbolChange%
HFCL116.03(8%)
SYNGENE467.65(8%)
FLUOROCHEM3602(7%)
IKS1654.7(6%)
DCMSHRIRAM1227.5(5%)
1 Day Top Losers
SymbolChange%
VEDL271.55(-65%)
WAAREEENER3118.8(-11%)
HEG596.05(-10%)
KFINTECH895.7(-8%)
NATIONALUM399.3(-8%)
ADANIENSOL1342.25(-5%)
FORCEMOT19904(-5%)
CEATLTD3445.2(-5%)

Top Performing Stocks from the same sector


Aarey Drugs & Pharmaceuticals Ltd.

79.5%

91.08

1 Month Performance

Balaxi Pharmaceuticals Ltd.

69.9%

26.63

1 Month Performance

Cohance Lifesciences Ltd.

60.3%

483.25

1 Month Performance

Gujarat Themis Biosyn Ltd.

60.2%

363.58

1 Month Performance

Vaishali Pharma Ltd.

55.9%

7.61

1 Month Performance

Kopran Ltd.

52.4%

164.63

1 Month Performance

Valiant Laboratories Ltd.

50.8%

77.82

1 Month Performance

Brooks Laboratories Ltd.

50.8%

55.98

1 Month Performance

Get Your Portfolio Reviewed

Stock of the Month
Stock of the Month